case_images: PMC2879548_01
case_images: Gottron's sing on the dorsal surface of the proximal interphalangeal joint. Erythematous areas at the bases of the fingernails are seen.
case_images: IJOL2010-401825.001.jpg
case_images: PMC2879548_01_IJOL2010-401825.001.jpg
case_images: fig1
case_images: For 1 month, the patient had noticed a systemic rash, the typical heliotrope coloration of the upper eyelids, Gottron's sign on the dorsal surface of his proximal interphalangeal joints, erythematous areas at the bases of the fingernails (Figure 1), dysphagia, and proximal muscle weakness of both extremities, but he and his family did not think that the symptoms were serious.
case_images: Case 1: Clinical Course. Treatment and serum CK levels are shown. CP: cyclophosphamide.
case_images: IJOL2010-401825.002.jpg
case_images: PMC2879548_01_IJOL2010-401825.002.jpg
case_images: fig2
case_images: The patient's clinical course is shown in Figure 2.
case_images: PMC2879548_02
case_images: Case 2: Clinical Course. Treatment and serum CK levels are shown.
case_images: IJOL2010-401825.003.jpg
case_images: PMC2879548_02_IJOL2010-401825.003.jpg
case_images: fig3
case_images: Figure 3. Five months after treatment was finished, positron emission tomography/computed tomography (PET-CT) showed no residual tumor so no neck dissections were carried out.
case_images: PET-CT. (a) Pre-treatment. Intense FDG uptake is detected in the left cervical region and the nasopharynx. Mild FDG uptake is detected in the muscles of the entire body, especially the upper extremities. (b) Post-treatment. FDG uptake with residual tumor is not detected. FDG uptake in the muscles is improved compared to pre-treatment.
case_images: IJOL2010-401825.004.jpg
case_images: PMC2879548_02_IJOL2010-401825.004.jpg
case_images: fig4
case_images: Pre- and posttreatment PET-CT scans are shown in Figure 4.